Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation [3]

Leukemia

Volumn 21, Issue 12, 2007, Pages 2540-2544

  Oran, B ^a   Giralt, S ^a   Couriel, D ^a   Hosing, C ^a   Shpall, E J ^a   de Meis, E ^a   Khouri, I F ^a   Qazilbash, M ^a   Anderlini, P ^a   Kebriaei, P ^a   Popat, U ^a   Carrasco Yalan, A ^a   Champlin, R E ^a   de Lima, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; GRAFT FAILURE; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PATIENT REFERRAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETREATMENT; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 36348967686     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404828     Document Type: Letter

References (7)

1. Frassoni F, Barrett AJ, Granena A, Ernst P, Garthon G, Kolb HJ et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases. Br J Haematol 1988; 70: 317-320.
2. Kumar L. Leukemia: Management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 12: 1710-1717.
3. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50-57.
4. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005; 36: 157-162.
5. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
6. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721-727.
7. Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: A survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000; 108 400-407.